Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
英夫利昔单抗（Remicade®）在低危骨髓增生异常综合征患者中的价值：欧洲癌症研究与治疗组织白血病组一项随机II期试验（EORTC 06023试验）的最终结果
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2011.044347
Baron, Frédéric; Suciu, Stefan; Amadori, Sergio; Muus, Petra; Zwierzina, Heinz; Denzlinger, Claudio; Delforge, Michel; Thyss, Antoine; Selleslag, Dominik; Indrak, Karel; Ossenkoppele, Gert; de Witte, Theo
